Recent Updates
Recently added Catalysts
ENVB Positive Sentiment Score: 75/100

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets [Microdose]

Monday, August 18, 2025 1 min read
Key Takeaway: Enveric Biosciences is gaining attention in the psychedelic therapeutics sector as it focuses on non-hallucinogenic neuroplastogens. This innovative approach aims to promote neuroplasticity without psychoactive effects, potentially making psychedelic-like benefits more accessible. The recent acquisition rumors in the sector have also heightened investor interest in companies like Enveric.
Price reaction · baseline $13.8 (2025-08-18T17:01:00.000Z) · hit during market hours · 1 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+3.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Enveric Biosciences focuses on non-hallucinogenic neuroplastogens.
  • The approach aims to make psychedelic-like benefits practical and scalable.
  • Investor interest in the psychedelic sector is rising.

Full Press Release Details

AbbVie’s rumored $1 billion acquisition of Gilgamesh Pharmaceuticals has amplified attention on the psychedelic therapeutics sector. Stocks of companies like Cybin, Mind Medicine, and GH Research have surged, driven by investor excitement over the promise of psychedelics in treating mental health disorders.
But while traditional psychedelic developers dominate headlines, Enveric Biosciences (NASDAQ: ENVB) has stayed quietly in the background, focusing on an equally groundbreaking, but less flashy, approach: non-hallucinogenic neuroplastogens, small molecules designed to promote neuroplasticity without psychoactive effects. This path represents a major leap forward in making psychedelic-like benefits practical, scalable, and clinically accessible.
Full Article >>

Frequently Asked Questions

What is Enveric Biosciences focusing on?

Enveric Biosciences is focusing on non-hallucinogenic neuroplastogens.

How do neuroplastogens benefit mental health?

Neuroplastogens promote neuroplasticity without psychoactive effects.

Why is investor interest in psychedelics rising?

Investor interest is rising due to the potential of psychedelics in treating mental health disorders.

What recent event has increased attention on psychedelics?

AbbVie's rumored $1 billion acquisition of Gilgamesh Pharmaceuticals has increased attention.

Tags: ENVB Viatris Investor Conferences Healthcare Enveric Biosciences psychedelic therapeutics neuroplastogens mental health non-hallucinogenic
Last updated: Aug 18, 2025

Biotech snapshot

Cash runway
$5M liquidity · $1M/mo burn
~4 mo
High dilution risk